OCX Quote, Financials, Valuation and Earnings

Fonar has a net margin of -312.02% compared to OncoCyte's net margin of 9.23%. OncoCyte's return on equity of -693.81% beat Fonar's return on equity of 5.33%.

OncoCyte has a consensus price target of $5.42, signalling upside risk potential of 60.73%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $2.1M, which are smaller than Fonar quarterly revenues of $27.2M. OncoCyte's net income of -$6.7M is lower than Fonar's net income of $2.5M. Notably, OncoCyte's price-to-earnings ratio is -- while Fonar's PE ratio is 11.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 15.28x versus 0.88x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of -312.02% compared to OncoCyte's net margin of -209.38%. OncoCyte's return on equity of -693.81% beat ProPhase Labs's return on equity of -144.22%.

OncoCyte has a consensus price target of $5.42, signalling upside risk potential of 60.73%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 4207.12%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $2.1M, which are larger than ProPhase Labs quarterly revenues of $1.4M. OncoCyte's net income of -$6.7M is lower than ProPhase Labs's net income of $4M. Notably, OncoCyte's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 15.28x versus 1.74x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -312.02% compared to OncoCyte's net margin of 6.16%. OncoCyte's return on equity of -693.81% beat Veracyte's return on equity of 2.85%.

OncoCyte has a consensus price target of $5.42, signalling upside risk potential of 60.73%. On the other hand Veracyte has an analysts' consensus of $40.50 which suggests that it could grow by 49.12%. Given that OncoCyte has higher upside potential than Veracyte, analysts believe OncoCyte is more attractive than Veracyte.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $2.1M, which are smaller than Veracyte quarterly revenues of $114.5M. OncoCyte's net income of -$6.7M is lower than Veracyte's net income of $7M. Notably, OncoCyte's price-to-earnings ratio is -- while Veracyte's PE ratio is 66.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 15.28x versus 4.63x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -312.02% compared to OncoCyte's net margin of -67.19%. OncoCyte's return on equity of -693.81% beat XWELL's return on equity of -153.74%.

OncoCyte has a consensus price target of $5.42, signalling upside risk potential of 60.73%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 678.38%. Given that XWELL has higher upside potential than OncoCyte, analysts believe XWELL is more attractive than OncoCyte.

OncoCyte has a beta of 0.953, which suggesting that the stock is 4.749% less volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $2.1M, which are smaller than XWELL quarterly revenues of $7M. OncoCyte's net income of -$6.7M is lower than XWELL's net income of -$4.7M. Notably, OncoCyte's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 15.28x versus 0.14x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.